Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Down 56.6% in March

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a large drop in short interest in March. As of March 15th, there was short interest totalling 53,200 shares, a drop of 56.6% from the February 28th total of 122,600 shares. Approximately 3.3% of the company’s stock are sold short. Based on an average daily trading volume, of 395,000 shares, the short-interest ratio is currently 0.1 days.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Bleichroeder LP acquired a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned 4.15% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is owned by hedge funds and other institutional investors.

Aptose Biosciences Stock Performance

NASDAQ APTO opened at $3.32 on Friday. The stock has a 50-day moving average of $4.57 and a 200 day moving average of $7.54. Aptose Biosciences has a one year low of $2.39 and a one year high of $51.61. The company has a market capitalization of $7.11 million, a price-to-earnings ratio of -1.12 and a beta of 1.14.

Analyst Ratings Changes

A number of equities research analysts have recently commented on APTO shares. Alliance Global Partners raised Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. HC Wainwright increased their price objective on shares of Aptose Biosciences from $2.00 to $6.00 and gave the company a “buy” rating in a research report on Friday. Finally, StockNews.com began coverage on shares of Aptose Biosciences in a report on Thursday. They issued a “sell” rating for the company. One analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $112.00.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.